Ozempic Activates Hunger Neurons to Sustain Fat Loss: Yale — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Yale researchers found that semaglutide activates AgRP hunger neurons in mice, the opposite of what scientists had assumed about how GLP-1 drugs reduce weight.
- Mice genetically engineered to lack AgRP neurons were unable to sustain weight loss on GLP-1 drugs, demonstrating those neurons are required for the drug's lasting effect.
- The study, published in PNAS and led by Mateus d'Ávila in Tamas Horvath's lab, combined electrophysiology, electron microscopy, and molecular biology to track brain responses during semaglutide treatment.
- GLP-1 medications such as Ozempic produce sustained weight loss of 10 to 15% or more, far exceeding older appetite suppressants that cut hunger nearly as effectively but fail to maintain results.
- The Yale team concluded that AgRP neurons, traditionally seen as obstacles to weight loss, may instead be part of the biological machinery that maintains it by helping coordinate fat loss during a drug-induced calorie deficit.
- The experiments were conducted in mice; the researchers explicitly note further work is needed to confirm the same mechanism operates in humans.
Why it matters: The finding reframes a $100-billion-dollar drug class's mechanism of action — the research team at Yale says it opens a concrete biological target for designing next-generation obesity therapies that are more effective or carry fewer side effects than current GLP-1 drugs.
Ask SkimNews
